Veridien Climate Action ETF
Limited financial coverage for CLIA.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This fund aims to achieve its investment objectives by allocating capital to equity securities, including American Depositary Receipts (ADRs), issued by companies worldwide. It focuses on U. S.
- IPO
- 2023
- HQ
- US
Get TickerSpark's AI analysis on CLIA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $21.19
- 52W Low
- $16.48
- 50D MA
- $19.37
- 200D MA
- $19.18
- Beta
- 1.72
- RSI (14)
- 38
- Avg Volume
- 36.44K
No earnings-call transcripts are available for CLIA yet.
- Free Float
- 0.0%
- Shares Outstanding
- 1.36M
- Float Shares
- 0
Our CLIA coverage
Recent articles, reports, and earnings notes.
No research on CLIA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLIA report →Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
businesswire.com · Aug 18
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
globenewswire.com · Jul 7
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
gurufocus.com · Jun 17
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual
gurufocus.com · May 31
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
gurufocus.com · May 30
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
gurufocus.com · May 29
Lumos Diagnostics Holdings Limited (LDXHF) Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy Transcript
seekingalpha.com · Mar 30
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
globenewswire.com · Feb 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.